Jazz Pharmaceuticals (FRA:J7Z) FCF Margin % : 13.76% (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Jazz Pharmaceuticals FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Jazz Pharmaceuticals's Free Cash Flow for the three months ended in Dec. 2023 was €128 Mil. Jazz Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was €928 Mil. Therefore, Jazz Pharmaceuticals's FCF Margin % for the quarter that ended in Dec. 2023 was 13.76%.

As of today, Jazz Pharmaceuticals's current FCF Yield % is 15.41%.

The historical rank and industry rank for Jazz Pharmaceuticals's FCF Margin % or its related term are showing as below:

FRA:J7Z' s FCF Margin % Range Over the Past 10 Years
Min: 14.38 Med: 27.42 Max: 37.44
Current: 27.42

During the past 13 years, the highest FCF Margin % of Jazz Pharmaceuticals was 37.44%. The lowest was 14.38%. And the median was 27.42%.

FRA:J7Z's FCF Margin % is ranked better than
93.51% of 1032 companies
in the Biotechnology industry
Industry Median: -148.935 vs FRA:J7Z: 27.42

Jazz Pharmaceuticals FCF Margin % Historical Data

The historical data trend for Jazz Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jazz Pharmaceuticals FCF Margin % Chart

Jazz Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

27.48

22.02

23.69

21.15

27.36

Jazz Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-4.36	35.38	30.40	31.16	13.76

Competitive Comparison of Jazz Pharmaceuticals's FCF Margin %

For the Biotechnology subindustry, Jazz Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Jazz Pharmaceuticals's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jazz Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Jazz Pharmaceuticals's FCF Margin % falls into.

Jazz Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Jazz Pharmaceuticals's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	961.974	/	3515.965
	=	27.36 %

Jazz Pharmaceuticals's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	127.68	/	927.944
	=	13.76 %

Jazz Pharmaceuticals FCF Margin % Related Terms

Thank you for viewing the detailed overview of Jazz Pharmaceuticals's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Jazz Pharmaceuticals (FRA:J7Z) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jazz Pharmaceuticals PLC (FRA:J7Z) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

JAZZ:USA JAZZ:Mexico

Address

Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7

Website

https://www.jazzpharmaceuticals.com

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Jazz Pharmaceuticals (FRA:J7Z) Headlines

No Headlines